Treatment Action Group (TAG) welcomes and celebrates the U.S. Food and Drug Administration’s (FDA) approval of Apretude brand cabotegravir, the first injectable medication for use as pre-exposure prophylaxis (PrEP) to reduce the risk of HIV transmission.
As we look forward to an end of an extremely challenging year—and past four years—we reflect on the remarkable resilience and impact of TAG, even and especially in these dark times.
December 2021 Update, October 2025: On September 30, 2025, the US Department of Justice announced that Serhat Gumrukcu was convicted by a jury on April 18, 2025 for his role in the murder for hire conspiracy. Update, June 2022: The…
November 2021 Examples of media coverage: Scientists report finding a second person to be ‘naturally’ cured of HIV, raising hopes for future treatments - Megan Molteni, STAT News, November 15, 2021 A Second Woman May Be Naturally Cured of HIV…
November 2021 Examples of media coverage: Research team develops vaccine that kills HIV in monkeys - The Asahi Shimbun, November 9, 2021 A New Vaccine Kills HIV in Monkeys. And It's Coming to Humans in 5 Years - Interesting Engineering,…
Developing an HIV vaccine is a difficult scientific challenge, but remains a critical priority. This handout provides an update on HIV vaccine research and a summary of results from the efficacy trials that have been conducted to date, and it…
Treatment Action Group (TAG) recognizes the importance of intentionally engaging the community broadly in our advocacy efforts, and we believe that the community should always be at the forefront of advocacy and research. Meaningful community engagement builds trust and fosters…
HIV advocacy laid the foundation for much of the work we do today. This handout was developed in collaboration with the Black AIDS Institute, HIV Vaccine Trials Network, and Southern AIDS Coalition. The handout provides a summary of the history…
HIV-specific broadly neutralizing antibodies (bNAbs) could have a role in treating, preventing, or even curing HIV. Some HIV-specific bNAbs are already being tested in clinical trials, both for prevention and treatment. This handout was developed in collaboration with the Black…
HIV science can be difficult to understand. This handout explains some of the unique scientific challenges presented by HIV. The handout was developed in collaboration with the Black AIDS Institute, HIV Vaccine Trials Network, and Southern AIDS Coalition.